Implicit|10|69||||249|2||and||Expansion.Conjunction||||Wr|Comm|Null|Null||||196..247|1|Revenue rose 23% to $100 million from $81.6 million|Inh|Null|Null|Null||||249..330|2|Net product sales accounted for $76 million, up from $57.5 million a year earlier|Inh|Null|Null|Null|||||||||
Explicit|10|69|483..486|4,0|But|||but|||Comparison.Concession.Contra-expectation||||Wr|Comm|Null|Null||||334..481|3|Sales of the heart drug TPA were $43.6 million, better than last year's depressed third period when the company sold just $29.1 million of the drug|Inh|Null|Null|Null||||487..576|4,1;4,2,0;4,2,1;4,2,2;4,3|TPA sales fell below levels for this year's first and second quarter sales of $48 million|Inh|Null|Null|Null|||||||578..595|4,2,3|cooling investors
Implicit|10|69||||597|5||as a result||Contingency.Cause.Result||||Wr|Comm|Null|Null||||578..595|4,2,3|cooling investors|Inh|Null|Null|Null||||597..691|5|Genentech stock fell 12.5 cents in trading yesterday on the New York Stock Exchange to $20.125|Inh|Null|Null|Null||||483..576|4,0;4,1;4,2,0;4,2,1;4,2,2;4,3|But TPA sales fell below levels for this year's first and second quarter sales of $48 million|||
Implicit|10|69||||813|7||whereas||Comparison.Contrast.Opposition||||Wr|Comm|Null|Null||||695..811|6|In the nine months, net income slid 21% to $28.4 million, or 33 cents a share, from $36 million, or 42 cents a share|Inh|Null|Null|Null||||813..869|7|Revenues climbed 18% to $289 million from $245.3 million|Inh|Null|Null|Null|||||||||
Explicit|10|69|1015..1018|9,0|But|||but|||Comparison.Concession.Contra-expectation||||Wr|Comm|Null|Null||||874..955|8,1|We continue to be on target for . . . increasing ÕTPAå sales 20% to 25% this year|Ot|Comm|Null|Null|958..1013|8,0;8,2;8,3;8,4;8,5;8,6|said founder and Chief Executive Officer Robert Swanson|1019..1059|9,1;9,2;9,3|some analysts remain sour on the company|Inh|Null|Null|Null|||||||||
Implicit|10|69||||1103|11||although||Comparison.Contrast.Juxtaposition||||Ot|Comm|Null|Null|1270..1345|13,1;13,2;13,3;13,4;13,5|said Denise Gilbert, an analyst with Montgomery Securities in San Francisco|1064..1101|10|TPA sales are down quarter to quarter|Inh|Null|Null|Null||||1103..1120|11,0|Expenses are flat|Inh|Null|Null|Null|||||||||
Explicit|10|69|1121..1124|11,1|and|||and|||Expansion.Conjunction||||Ot|Comm|Null|Null|1270..1345|13,1;13,2;13,3;13,4;13,5|said Denise Gilbert, an analyst with Montgomery Securities in San Francisco|1103..1120|11,0|Expenses are flat|Inh|Null|Null|Null||||1125..1143|11,2|that's a good sign|Inh|Null|Null|Null|||||||||
Implicit|10|69||||1145|12||also||Expansion.Conjunction||||Ot|Comm|Null|Null|1270..1345|13,1;13,2;13,3;13,4;13,5|said Denise Gilbert, an analyst with Montgomery Securities in San Francisco|1103..1120|11,0|Expenses are flat|Inh|Null|Null|Null||||1145..1222|12|There's contract revenue from {limited research and development} partnerships|Inh|Null|Null|Null|||||||||
Explicit|10|69|1224..1227|13,0,0|But|||but|||Comparison.Contrast||||Ot|Comm|Null|Null|1270..1345|13,1;13,2;13,3;13,4;13,5|said Denise Gilbert, an analyst with Montgomery Securities in San Francisco|1145..1222|12|There's contract revenue from {limited research and development} partnerships|Inh|Null|Null|Null||||1228..1267|13,0,1;13,0,2;13,0,3|I still think the fundamentals are poor|Inh|Null|Null|Null|||||||||
Explicit|10|69|1499..1502|15,0,0|And|||and|||Expansion.Conjunction||||Wr|Comm|Null|Null||||1349..1497|14|Genentech faces competition in the cardiac-drug market from SmithKline Beecham PLC's heart drug Eminase, expected to receive market approval shortly|Inh|Null|Null|Null||||1503..1587|15,0,1;15,0,2|Genentech isn't likely to have any new products ready for market until at least 1992|Ot|Comm|Null|Null|1589..1606|15,1;15,2;15,3;15,4|Ms. Gilbert added||||||
Implicit|10|69||||1609|16||furthermore||Expansion.Conjunction||||Wr|Comm|Null|Null||||1349..1587|14;15,0|Genentech faces competition in the cardiac-drug market from SmithKline Beecham PLC's heart drug Eminase, expected to receive market approval shortly.And Genentech isn't likely to have any new products ready for market until at least 1992|Ot|Comm|Null|Null|1589..1606|15,1;15,2;15,3;15,4|Ms. Gilbert added|1609..1692|16,1|The company's stock is trading at 40 times next year's numbers, and that's too much|Ot|Comm|Null|Null|1695..1703|16,0;16,2;16,3;16,4;16,5;16,6|she said||||||
Explicit|10|69|1673..1676|16,1,2|and|||and|||Expansion.Conjunction||||Ot|Comm|Null|Null|1695..1703|16,0;16,2;16,3;16,4;16,5;16,6|she said|1609..1671|16,1,0|The company's stock is trading at 40 times next year's numbers|Inh|Null|Null|Null||||1677..1692|16,1,3|that's too much|Inh|Null|Null|Null|||||||||
